Karyopharm Therapeutics, Inc. (KPTI) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1156492,
    "name": "Karyopharm Therapeutics, Inc.",
    "stock_name": "Karyopharm Therapeutics, Inc.",
    "full_name": "Karyopharm Therapeutics, Inc.",
    "name_url": "stocks-analysis/karyopharm-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "5.91",
    "chg": 0.55,
    "chgp": "10.26%",
    "dir": 1,
    "prev_price": "5.36",
    "mcapval": "54.20",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US48576U1060",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "269.48 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/karyopharm-therapeutics-inc-1156492-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Karyopharm Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-karyopharm-therapeutics-inc-technically-bullish-or-bearish-3547044",
        "imagepath": "",
        "date": "2025-09-20 19:45:43",
        "description": "As of 13 August 2025, the technical trend for Karyopharm Therapeutics, Inc. has changed from bearish to mildly bearish. Currently, the weekly MACD and Bollinger Bands indicate a mildly bullish stance, while the daily moving averages and the weekly KST suggest a mildly bearish outlook. The RSI shows no signal in both weekly and monthly time frames, and Dow Theory reflects a mildly bearish trend on the weekly chart with no trend on the monthly. \n\nIn terms of performance, Karyopharm has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -43.52% compared to the S&P 500's 12.22%, and a one-year return of -48.13% versus 17.14% for the benchmark. Overall, the current technical stance is mildly bearish, indicating some weakness despite a few bullish signals...."
      },
      {
        "title": "Is Karyopharm Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-karyopharm-therapeutics-inc-overvalued-or-undervalued-3543487",
        "imagepath": "",
        "date": "2025-09-20 18:20:46",
        "description": "As of 15 March 2018, Karyopharm Therapeutics, Inc. has moved from a grade of does not qualify to risky, indicating increased concerns about its valuation. The company appears to be overvalued given its negative valuation metrics, including a Price to Book Value of -0.19, an EV to EBIT of -1.25, and an EV to EBITDA of -1.26. Compared to peers, Karyopharm's EV to EBITDA ratio of -1.6265 is significantly worse than XOMA Corp.'s -22.9484 and Zevra Therapeutics, Inc.'s 7.4373, highlighting its relative weakness in the industry.\n\nThe stock's performance has been notably poor, with a year-to-date return of -43.52% compared to the S&P 500's 12.22%, and a staggering decline of -97.66% over the past five years, while the S&P 500 has gained 96.61%. This stark contrast in returns further reinforces the notion that Karyopharm is overvalued in its current state...."
      }
    ],
    "total": 7,
    "sid": "1156492",
    "stock_news_url": "https://www.marketsmojo.com/news/karyopharm-therapeutics-inc-1156492"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Karyopharm Therapeutics, Inc. technically bullish or bearish?

2025-09-20 19:45:43

As of 13 August 2025, the technical trend for Karyopharm Therapeutics, Inc. has changed from bearish to mildly bearish. Currently, the weekly MACD and Bollinger Bands indicate a mildly bullish stance, while the daily moving averages and the weekly KST suggest a mildly bearish outlook. The RSI shows no signal in both weekly and monthly time frames, and Dow Theory reflects a mildly bearish trend on the weekly chart with no trend on the monthly. In terms of performance, Karyopharm has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -43.52% compared to the S&P 500's 12.22%, and a one-year return of -48.13% versus 17.14% for the benchmark. Overall, the current technical stance is mildly bearish, indicating some weakness despite a few bullish signals....

Is Karyopharm Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:20:46

As of 15 March 2018, Karyopharm Therapeutics, Inc. has moved from a grade of does not qualify to risky, indicating increased concerns about its valuation. The company appears to be overvalued given its negative valuation metrics, including a Price to Book Value of -0.19, an EV to EBIT of -1.25, and an EV to EBITDA of -1.26. Compared to peers, Karyopharm's EV to EBITDA ratio of -1.6265 is significantly worse than XOMA Corp.'s -22.9484 and Zevra Therapeutics, Inc.'s 7.4373, highlighting its relative weakness in the industry. The stock's performance has been notably poor, with a year-to-date return of -43.52% compared to the S&P 500's 12.22%, and a staggering decline of -97.66% over the past five years, while the S&P 500 has gained 96.61%. This stark contrast in returns further reinforces the notion that Karyopharm is overvalued in its current state....

View All News